Differential evaluation of encephalitis of unknown origin with subacute onset of seizures, confusion, memory loss, and/or behavioral change. For extended version of this panel, refer to Autoimmune Encephalitis Extended Panel, Serum (3001431). For adults and patients with suspicion of cancer, additional evaluation of paraneoplastic autoantibodies is recommended; refer to Paraneoplastic Antibodies (PCCA/ANNA) by IFA with Reflex to Titer and Immunoblot (2007961).
Semi-Quantitative Indirect Fluorescent Antibody/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Quantitative Radioimmunoassay
Serum Separator Tube (SST).
Separate from cells ASAP or within 2 hours of collection. Transfer three 1 mL aliquots of serum to individual ARUP Standard Transport Tubes. (Min: 0.5 mL/aliquot)
Amniotic fluid, ocular fluid, peritoneal fluid, synovial fluid, CSF, or plasma. Contaminated, hemolyzed, icteric, or lipemic specimens.
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 month (avoid repeated freeze/thaw cycles)
|2004221||N-methyl-D-Aspartate Receptor Antibody, IgG, Serum with Reflex to Titer||< 1:10|
|2001771||Glutamic Acid Decarboxylase Antibody||0.0-5.0 IU/mL|
|2004890||Voltage-Gated Potassium Channel (VGKC) Antibody, Serum||
|2003036||Aquaporin-4 Receptor Antibody||Effective October 3, 2016
|2013320||Aquaporin-4 Receptor Antibody, IgG by IFA with Reflex to Titer, Serum||Less than 1:10|
|2009456||Leucine-Rich, Glioma-Inactivated Protein 1 Antibody, IgG with Reflex to Titer, Serum||Less than 1:10|
|2009452||Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, Serum||Less than 1:10|
Refer to report
Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
AQP4: If AQP4 antibody IgG by ELISA is positive, then AQP4 antibody IgG by IFA will be added. If AQP4 antibody IgG by IFA is positive, then an AQP4 antibody IgG titer will be added. Additional charges apply.
VGKC: If VGKC is Indeterminate or Positive, LGI1 Antibody IgG and CASPR2 Antibody IgG will be added. If LGI1 antibody IgG is positive, then LGI1 antibody IgG titer will be added. If CASPR2 antibody IgG is positive, then CASPR2 antibody IgG titer will be added. Additional charges apply.
NMDA: If NMDA antibody IgG is positive, then an NMDA antibody IgG titer is reported. Additional charges apply.
83519; 83516; 86255; 86341; if reflexed add 86255 x2, if further reflexed add 86256 per titer; if reflexed add 86256; if reflexed add 86255, if further reflexed add 86256
|Component Test Code*||Component Chart Name||LOINC|
|2001772||Glutamic Acid Decarboxylase Antibody||56540-8|
|2003121||Aquaporin-4 Receptor Antibody||61430-5|
|2004222||N-methyl-D-Aspartate Receptor Ab, Serum||80221-5|
|2004890||Voltage-Gated Potassium Channel Ab, Ser||41871-5|